Antiandrogen Therapy With or Without Axitinib Before Surgery in Treating Patients With Previously Untreated Prostate Cancer With Known or Suspected Lymph Node Metastasis

Inclusion Criteria: * Patients with adenocarcinoma of the prostate that in the opinion of the urologist could be resected after response to systemic therapy; ductal adenocarcinoma is permitted * Patients must be regarded as acceptable surgical risk for radical prostatectomy and confirm their intention to undergo radical prostatectomy at the end of the pre-surgical therapy * Eastern Cooperative Oncology Group (ECOG) performance status 2 or better * All patients must have thorough tumor staging and meet at least one of the following criteria: * Either lymph node biopsy or lymph node dissection demonstrating lymph node metastasis by prostate cancer * Non-bulky (\< 5 cm) regional pelvic or distant lymphadenopathy visualized on computed tomography (CT)/magnetic resonance imaging (MRI) scan; lymph node biopsy is required if \< 2.0 cm or in atypical distribution * Primary tumor Gleason score \>= 8 and serum prostate-specific antigen (PSA) concentration \>= 25 ng/mL, indicating high risk of occult lymph node metastases * Primary clinical tumor stage of T3 and Gleason score \>= 7, indicating high risk of occult lymph node metastases * Primary tumor stage T4, indicating high risk of occult lymph node metastases; patients in any of these groups and less than 3 sites of non-predominantly lytic bone metastasis will be still considered eligible for the trial; the 2010 American Joint Committee on Cancer (AJCC) staging system will be followed * Prior hormonal therapy (luteinizing…